The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis
- 1 September 2020
- journal article
- research article
- Published by Elsevier BV in Bone
- Vol. 138, 115478
- https://doi.org/10.1016/j.bone.2020.115478
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass GainsJournal of Bone and Mineral Research, 2020
- Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical TrialJournal of Bone and Mineral Research, 2019
- Stopping DenosumabCurrent Osteoporosis Reports, 2019
- Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTSBone, 2017
- Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its ExtensionJournal of Bone and Mineral Research, 2017
- Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatmentActa Endocrinologica, 2017
- Clinical Features of 24 Patients With Rebound‐Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional CasesJournal of Bone and Mineral Research, 2017
- Observations following discontinuation of long-term denosumab therapyOsteoporosis International, 2017
- Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone MassJournal of Clinical Endocrinology & Metabolism, 2011